¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.
¼¼°è ±Þ¼º ½Å¼Õ»ó(AKI) Ä¡·á ½ÃÀåÀº 2025³â 19¾ï 6,000¸¸ ´Þ·¯, 2032³â¿¡´Â 34¾ï 3,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, 2025-2032³â°£ ¿¬Æò±Õ 8.3% ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
º¸°í ¹üÀ§ |
º¸°í¼ »ó¼¼ ³»¿ë |
±âÁØ ¿¬µµ |
2024³â |
2025³â ½ÃÀå ±Ô¸ð |
19¾ï 6,000¸¸ ´Þ·¯ |
½ÇÀû µ¥ÀÌÅÍ |
2020-2024³â |
¿¹Ãø ±â°£ |
2025-2032³â |
¿¹Ãø ±â°£(2025-2032³â) CAGR |
8.30% |
2032³â ±Ý¾× ¿¹Ãø |
34¾ï 3,000¸¸ ´Þ·¯ |
±×¸². 2025³â Áö¿ªº° ±Þ¼º ½Å¼Õ»ó(AKI) Ä¡·á ½ÃÀå Á¡À¯À²(%)

±Þ¼º½Å¼Õ»ó(AKI)Àº ½ÅÀåÀÇ ±Þ°ÝÇÑ ±â´É ÀúÇÏ·Î ÀÎÇØ Á¤»óÀûÀ¸·Î ½ÅÀå¿¡¼ Á¦°ÅµÇ¾î¾ß ÇÒ ³ëÆó¹°ÀÌ Ç÷¾×¿¡ ÃàÀûµÇ´Â °ÍÀ» ¸»ÇÕ´Ï´Ù. ´õ ÀÌ»óÀÇ ½ÅÀå ¼Õ»óÀ̳ª ½ÅºÎÀüÀ» ¿¹¹æÇϱâ À§ÇØ ½Å¼ÓÇÑ Ä¡·á°¡ ÇÊ¿äÇÑ ½É°¢ÇÑ »óÅÂÀÔ´Ï´Ù. ¼¼°è ±Þ¼º½Å¼Õ»ó Ä¡·áÁ¦ ½ÃÀåÀÇ ¼ºÀåÀ» ÁÖµµÇÏ´Â °ÍÀº AKIÀÇ À§ÇèÀ» ³ôÀÌ´Â ´ç´¢º´, °íÇ÷¾Ð°ú °°Àº µ¿¹ÝÁúȯÀÇ À¯º´·ü Áõ°¡ÀÔ´Ï´Ù. ¶ÇÇÑ, »õ·Î¿î ¾à¹° ¹× Ä¡·á Á¢±Ù¹ýÀÇ °³¹ß·Î ÀÎÇØ ȯÀÚÀÇ Ä¡·á ¿É¼ÇÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ±×·¯³ª AKI¿¡ ´ëÇÑ È¯ÀÚ ¹× ÀÇ·áÁøÀÇ ÀÎ½Ä ºÎÁ·Àº ½ÃÀå ¼ºÀåÀ» ÀúÇØÇÏ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù.
½ÃÀå ¿ªÇÐ
¼¼°è ±Þ¼º ½Å¼Õ»ó(AKI) Ä¡·áÁ¦ ½ÃÀåÀÇ ¼ºÀåÀ» ÁÖµµÇϰí ÀÖ´Â °ÍÀº ³ëÈ¿¡ µû¸¥ ½ÅÀå ±â´É ÀúÇÏ·Î AKI¿¡ Ãë¾àÇÑ ³ë³âÃþ Áõ°¡ÀÔ´Ï´Ù. UN¿¡ µû¸£¸é, 65¼¼ ÀÌ»ó ³ëÀÎ Àα¸´Â 2050³â±îÁö 15¾ï ¸í ÀÌ»ó¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù. »ýȰ½À°üÀÇ º¯È·Î ÀÎÇÑ ¸¸¼º ½ÅÀåÁúȯÀÇ À¯º´·ü Áõ°¡µµ ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µÉ °ÍÀÔ´Ï´Ù. ±×·¯³ª ½ÅÀå ´ëü ¿ä¹ýÀÇ ³ôÀº ºñ¿ëÀº º¸±ÞÀ» Á¦ÇÑÇÒ ¼ö ÀÖÀ¸¸ç, AKI Á¶±â Áø´Ü¿¡ ´ëÇÑ ÀÎ½Ä ºÎÁ·Àº ½ÃÀå ¼ºÀåÀ» ÀúÇØÇÒ ¼ö ÀÖÀ¸¸ç, AKI¸¦ Á¶±â¿¡ ¹ß°ßÇÒ ¼ö ÀÖ´Â ¹ÙÀÌ¿À¸¶Ä¿ÀÇ °³¹ßÀº ½ÃÀå °³Ã´ ±â¾÷¿¡°Ô ÀÌ ºÎ¹®¿¡¼ »ç¾÷À» È®ÀåÇÒ ¼ö ÀÖ´Â ±âȸ·Î ÀÛ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. ü¾× »óÅÂÀÇ ½Ç½Ã°£ ¸ð´ÏÅ͸µÀº ½Ç½Ã°£ ¸ÂÃãÇü Äɾ ÀǹÌÇÕ´Ï´Ù. µðÁöÅÐ Çコ ¼Ö·ç¼ÇÀº ¿ø°Ý ȯÀÚ °ü¸®¿¡µµ µµ¿òÀÌ µË´Ï´Ù.
º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡
¼¼°èÀÇ ±Þ¼º ½ÅÀå¾Ö Ä¡·áÁ¦ ½ÃÀåÀ» »ó¼¼ÇÏ°Ô ºÐ¼®ÇßÀ¸¸ç, 2024³âÀ» ±âÁØ ¿¬µµ·Î ÇÏ¿© ¿¹Ãø ±â°£(2025-2032³â) ½ÃÀå ±Ô¸ð(10¾ï ´Þ·¯)¿Í ¿¬Æò±Õ ¼ºÀå·ü(CAGR)À» Á¶»çÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
¶ÇÇÑ, ´Ù¾çÇÑ ºÎ¹®¿¡ °ÉÄ£ ÀáÀçÀû ¼öÀÍ ±âȸ¸¦ ¹àÈ÷°í, ÀÌ ½ÃÀåÀÇ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾È ¸ÅÆ®¸¯½º¸¦ ¼³¸íÇÕ´Ï´Ù.
¶ÇÇÑ ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, ½ÅÁ¦Ç° Ãâ½Ã ¹× ½ÂÀÎ, ½ÃÀå µ¿Çâ, Áö¿ªº° Àü¸Á, ÁÖ¿ä ±â¾÷ÀÇ °æÀï Àü·« µî¿¡ ´ëÇÑ Áß¿äÇÑ °íÂûÀ» Á¦°øÇÕ´Ï´Ù.
¼¼°è ±Þ¼º ½Å¼Õ»ó(AKI) Ä¡·áÁ¦ ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷ ÇÁ·ÎÆÄÀÏÀ» ±â¾÷ °³¿ä, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÁÖ¿ä Æ¯Â¡, ½ÇÀû, Àü·« µîÀÇ ÆÄ¶ó¹ÌÅ͸¦ ±âÁØÀ¸·Î Á¤¸®ÇÏ¿© ¼ö·ÏÇÏ¿´½À´Ï´Ù.
ÁÖ¿ä Á¶»ç ´ë»ó ±â¾÷À¸·Î´Â Fresenius Medical Care AG & Co.KGaA, Baxter, Angion Biomedica Corp, AM-Pharma, Quark Pharmaceuticals, Inc. µîÀÌ ÀÖ½À´Ï´Ù.
ÀÌ º¸°í¼ÀÇ ÅëÂû·ÂÀ» ÅëÇØ ¸¶ÄÉÆÃ ´ã´çÀÚ¿Í ±â¾÷ °æ¿µÁøÀº ÇâÈÄ Á¦Ç° Ãâ½Ã, À¯ÇüÈ, ½ÃÀå È®´ë, ¸¶ÄÉÆÃ Àü¼ú¿¡ ´ëÇÑ Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù.
¼¼°è ±Þ¼º ½ÅÀå Áúȯ Ä¡·á ½ÃÀå º¸°í¼´Â ÅõÀÚÀÚ, °ø±Þ¾÷ü, Á¦Ç° Á¦Á¶¾÷ü, À¯Åë¾÷ü, ½Å±Ô ½ÃÀå ÁøÃâ±â¾÷, À繫 ºÐ¼®°¡ µî ÀÌ »ê¾÷ÀÇ ´Ù¾çÇÑ ÀÌÇØ°ü°èÀÚ¸¦ ´ë»óÀ¸·Î ÇÕ´Ï´Ù.
ÀÌÇØ°ü°èÀÚµéÀº ¼¼°è ±Þ¼º ½ÅÀå Áúȯ Ä¡·á ½ÃÀå ºÐ¼®¿¡ »ç¿ëµÇ´Â ´Ù¾çÇÑ Àü·« ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ÀÇ»ç°áÁ¤À» ½±°Ô ³»¸± ¼ö ÀÖ½À´Ï´Ù.
¸ñÂ÷
Á¦1Àå Á¶»ç ¸ñÀû°ú ÀüÁ¦Á¶°Ç
Á¦2Àå ½ÃÀå Àü¸Á
Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®
- ½ÃÀå ¿ªÇÐ
- ¿µÇ⠺м®
- ±ÔÁ¦ ½Ã³ª¸®¿À
- Á¦Ç° ¹ß¸Å/½ÂÀÎ
- PEST ºÐ¼®
- Porter's Five Forces ºÐ¼®
- ÀμöÇÕº´(M&A) ½Ã³ª¸®¿À
Á¦4Àå ¼¼°èÀÇ ±Þ¼º ½Å¼Õ»ó(AKI) Ä¡·á ½ÃÀå, À¯Çüº°, 2020-2032³â(10¾ï ´Þ·¯)
- ¼·Ð
- Prerenal Acute Kidney Injury
- Intrinsic Renal Acute Kidney Injury
- Postrenal Acute Kidney Injury
Á¦5Àå ¼¼°èÀÇ ±Þ¼º ½Å¼Õ»ó(AKI) Ä¡·á ½ÃÀå, Ä¡·áº°, 2020-2032³â(10¾ï ´Þ·¯)
Á¦6Àå ¼¼°èÀÇ ±Þ¼º ½Å¼Õ»ó(AKI) Ä¡·á ½ÃÀå, À¯Åë ä³Îº°, 2020-2032³â(10¾ï ´Þ·¯)
- ¼·Ð
- º´¿ø ¾à±¹
- ¼Ò¸Å ¾à±¹
- ¿Â¶óÀÎ ¾à±¹
Á¦7Àå ¼¼°èÀÇ ±Þ¼º ½Å¼Õ»ó(AKI) Ä¡·á ½ÃÀå, Áö¿ªº°, 2020-2032³â(10¾ï ´Þ·¯)
- ¼·Ð
- ºÏ¹Ì
- ¶óƾ¾Æ¸Þ¸®Ä«
- À¯·´
- ¾Æ½Ã¾ÆÅÂÆò¾ç
- 秵- ¾ÆÇÁ¸®Ä«
Á¦8Àå °æÀï ±¸µµ
- Angion Biomedica Corp.
- AM-Pharma
- Quark Pharmaceuticals, Inc.
- Baxter International, Inc.
- Fresenius Medical Care AG & Co. KGaA
- Braun Melsungen AG
- Asahi Kasei Medical Co., Ltd.
- LG Chem
- Kringle Pharma, Inc.
- AstraZeneca
- Amgen Inc.
- Gilead Sciences
- Roche
- Merck & Co., Inc.
- Pfizer Inc.
- Sanofi
- Bristol-Myers Squibb
- Eli Lilly and Company
- Novartis AG
- AbbVie Inc.
Á¦9Àå ¾Ö³Î¸®½ºÆ® Ãßõ »çÇ×
- À¶¼º°ú ¼èÅð
- Coherent Opportunity Map
Á¦10Àå Âü°í ¹®Çå°ú Á¶»ç ¹æ¹ý
- Âü°í ¹®Çå
- Á¶»ç ¹æ¹ý
- ÃâÆÇ»ç¿¡ ´ëÇØ
LSH 25.04.02
Global Acute Kidney Injury Treatment Market is estimated to be valued at USD 1.96 Bn in 2025 and is expected to reach USD 3.43 Bn by 2032, growing at a compound annual growth rate (CAGR) of 8.3% from 2025 to 2032.
Report Coverage |
Report Details |
Base Year: |
2024 |
Market Size in 2025: |
USD 1.96 Bn |
Historical Data for: |
2020 To 2024 |
Forecast Period: |
2025 To 2032 |
Forecast Period 2025 to 2032 CAGR: |
8.30% |
2032 Value Projection: |
USD 3.43 Bn |
Figure. Acute Kidney Injury Treatment Market Share (%), By Region 2025

Acute kidney injury (AKI) refers to an abrupt loss of kidney function, resulting in the build-up of waste products in the blood that would normally be removed by the kidneys. It is a serious condition that requires prompt medical care to prevent further kidney damage and failure. Global acute kidney injury treatment market growth is driven by rising prevalence of comorbid conditions such as diabetes and hypertension that increases the risk of AKI. Furthermore, development of novel drugs and treatment approaches has expanded therapeutic options for patients. However, lack of awareness among people and healthcare providers about AKI can hamper the market growth.
Market Dynamics:
Global acute kidney injury treatment market growth is driven by rising geriatric population who are more susceptible to AKI due to age-related decline in kidney function. According to the United Nations, the number of people aged 65 years and above is projected to reach over 1.5 billion by 2050. Growing prevalence of chronic kidney diseases due to lifestyle changes can also drive the market growth. However, high costs associated with renal replacement therapies can limit widespread adoption. Lack of awareness about early diagnosis of AKI can hamper the market growth. Development of biomarkers for early detection of AKI presents lucrative opportunities for market players to expand their offerings in this area. Real-time monitoring of fluid status offers real-time customized care. Digital health solutions can also aid remote patient management.
Key features of the study:
This report provides in-depth analysis of the global acute kidney injury treatment market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global acute kidney injury treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Fresenius Medical Care AG & Co. KGaA, Baxter, Angion Biomedica Corp, AM-Pharma, and Quark Pharmaceuticals, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global acute kidney injury treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global acute kidney injury treatment market
Detailed Segmentation-
- Type Insights (Revenue, USD Bn, 2020 - 2032)
- Prerenal Acute Kidney Injury
- Intrinsic Renal Acute Kidney Injury
- Postrenal Acute Kidney Injury
- Treatment Insights (Revenue, USD Bn, 2020 - 2032)
- Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Angion Biomedica Corp.
- AM-Pharma
- Quark Pharmaceuticals, Inc.
- Baxter International, Inc.
- Fresenius Medical Care AG & Co. KGaA
- Braun Melsungen AG
- Asahi Kasei Medical Co., Ltd.
- LG Chem
- Kringle Pharma, Inc.
- AstraZeneca
- Amgen Inc.
- Gilead Sciences
- Roche
- Merck & Co., Inc.
- Pfizer Inc.
- Sanofi
- Bristol-Myers Squibb
- Eli Lilly and Company
- Novartis AG
- AbbVie Inc.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Acute Kidney Injury Treatment Market, By Type
- Global Acute Kidney Injury Treatment Market, By Treatment
- Global Acute Kidney Injury Treatment Market, By Distribution Channel
- Global Acute Kidney Injury Treatment Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
4. Global Acute Kidney Injury Treatment Market, By Type, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Prerenal Acute Kidney Injury
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Intrinsic Renal Acute Kidney Injury
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Postrenal Acute Kidney Injury
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
5. Global Acute Kidney Injury Treatment Market, By Treatment, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021- 2032
- Segment Trends
- Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
6. Global Acute Kidney Injury Treatment Market, By Distribution Channel, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
7. Global Acute Kidney Injury Treatment Market, By Region, 2020 - 2032, (USD Bn)
- Introduction
- Market Share (%) Analysis, 2025,2028 & 2032, (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Treatment, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
- Latin America
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Treatment, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Treatment, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Treatment, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Treatment, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Treatment, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, (USD Bn)
- South Africa
- North Africa
- Central Africa
8. Competitive Landscape
- Angion Biomedica Corp.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AM-Pharma
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Quark Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Baxter International, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Fresenius Medical Care AG & Co. KGaA
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Braun Melsungen AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Asahi Kasei Medical Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- LG Chem
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Kringle Pharma, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AstraZeneca
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Amgen Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Gilead Sciences
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Roche
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck & Co., Inc.
- Pfizer Inc.
- Sanofi
- Bristol-Myers Squibb
- Eli Lilly and Company
- Novartis AG
- AbbVie Inc.
9. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
10. References and Research Methodology
- References
- Research Methodology
- About us